Studies of the interactions of antibodies with their Fc receptors, with a particular focus on the neonatal Fc receptor (FcRn) and its relationship with IgG and albumin. In addition, we are investigating how FcRn acts as a transporter in different cell types of the body. The studies will unravel the basic structural and cellular mechanisms that govern the functions of FcRn. Such knowledge offers opportunities for development of novel drug concepts that will secure improved half-life and biodistribution.
Studies of the mechanisms of infections at different body sites and how humoral immunity fights and restricts infection and virus replication. In particular, we are studying how antibodies contribute to protection against infectious diseases, and how FcRn and tripartite motif containing 21 (TRIM21) take part in cellular protection. Such knowledge can be utilized to develop novel antibody technologies tailored to combat infectious diseases.
Fernández-Quintero ML, Ljungars A, Waibl F, Greiff V, Andersen JT, Gjølberg TT, Jenkins TP, Voldborg BG, Grav LM, Kumar S, Georges G, Kettenberger H, Liedl KR, Tessier PM, McCafferty J, Laustsen AH(2023) Assessing developability early in the discovery process for novel biologics MAbs, 15(1), 2171248 DOI 10.1080/19420862.2023.2171248, PubMed 36823021
Gjølberg TT, Wik JA, Johannessen H, Krüger S, Bassi N, Christopoulos PF, Bern M, Foss S, Petrovski G, Moe MC, Haraldsen G, Fosse JH, Skålhegg BS, Andersen JT, Sundlisæter E(2023) Antibody blockade of Jagged1 attenuates choroidal neovascularization Nat Commun, 14(1), 3109 DOI 10.1038/s41467-023-38563-w, PubMed 37253747
Lustig M, Chan C, Jansen JHM, Bräutigam M, Kölling MA, Gehlert CL, Baumann N, Mester S, Foss S, Andersen JT, Bastian L, Sondermann P, Peipp M, Burger R, Leusen JHW, Valerius T(2023) Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells Front Immunol, 14, 1178817 DOI 10.3389/fimmu.2023.1178817, PubMed 37346044